SPARC shares soar 20% after US district court passes favourable judgement for Sezaby PRV

Representative image

The shares of Sun Pharma Advanced Research Company (SPARC) jumped 20 percent on December 2. This comes after a US district court passed an order in favour of the company for its 'Sezaby' injection.

The shares of the pharma company hit the upper circuit at Rs 161.02 apiece, the highest level seen by the stock since end of July this year.

Here's what triggered SPARC's share price rally:

In an exchange filing, SPARC announced that the US District Court for the District of Columbia has granted summary judgement in favour of the company in regard with the issuance of Priority Review Voucher (PRV) associated with the approval of Sezaby.

The court granted SPARC’s motion for summary judgment and held that "FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved' as that term is used in the statute". It has allowed 60 days to appeal against the motion.

Speaking about the development, SPARC CEO Anil Raghavan said, "We are pleased with the ruling issued today by the U.S. District Court, as it validates SPARC’s long held position on this matter."

Sezaby is a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium powder for injection. It was approved by the US FDA for the treatment of neonatal seizures.

SPARC share price:

The sharp rise in the share price comes on the back of strong trading volumes. Nearly 2.6 crore shares have changed hands in trade so far. This is around 117 times that of the stock’s 10-day average volumes.

The shares are currently trading higher than its 200-day average. Despite today's sharp gains, SPARC shares have fallen nearly 19 percent in the past six months, and are down nearly 20 percent in 2025 so far.

Follow all LIVE updates from the stock markets here.